104 related articles for article (PubMed ID: 3354562)
1. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
2. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
Katoh O; Kimura A; Itoh T; Kuramoto A
Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
[TBL] [Abstract][Full Text] [Related]
3. A reversible defect of platelet PDGF content in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
[TBL] [Abstract][Full Text] [Related]
4. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
6. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
Kimura A; Katoh O; Kuramoto A
Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
[TBL] [Abstract][Full Text] [Related]
7. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
[TBL] [Abstract][Full Text] [Related]
8. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
Rueda F; Piñol G; Marti F; Pujol-Moix N
Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
[TBL] [Abstract][Full Text] [Related]
10. [Basic and clinical study of platelet-derived growth factor gene expression].
Takimoto Y; Kimura A
Rinsho Ketsueki; 1994 Apr; 35(4):364-9. PubMed ID: 8028181
[TBL] [Abstract][Full Text] [Related]
11. Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.
Martyré MC
Leuk Lymphoma; 1991; 6(1):1-6. PubMed ID: 27457569
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
14. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
15. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
16. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
17. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
18. Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: ultrastructure and peroxidase reaction.
Maldonado JE; Pintado T; Pierre RV
Blood; 1974 Jun; 43(6):797-809. PubMed ID: 4524752
[No Abstract] [Full Text] [Related]
19. Effect of retinoic acid on platelet-derived growth factor (PDGF) bioactivity and type-B PDGF receptors in normal and psoriatic human fibroblasts.
Raynaud F; Gerbaud P; Gu XF; Donnadieu M; Evain-Brion D
J Invest Dermatol; 1991 Jan; 96(1):111-5. PubMed ID: 1846164
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
